ストックスクリーナーアプリを入手
8.76
0.69%
0.06
アフターアワーズ：
8.75
-0.010
-0.11%
前日終値:
$8.70
開ける：
$8.67
24時間の取引高:
4.58M
Relative Volume:
0.74
時価総額：
$2.28B
収益：
$6.28B
当期純損益:
$700.00M
株価収益率:
3.2538
EPS:
2.6922
ネットキャッシュフロー:
$537.00M
1週間 パフォーマンス:
+8.82%
1か月 パフォーマンス:
+25.68%
6か月 パフォーマンス:
-9.03%
1年 パフォーマンス:
-45.86%
1日の値動き範囲:
$8.61
$8.80
1週間の範囲:
$7.96
$8.80
52週間の値動き範囲:
$6.18
$17.23
Organon Co Stock (OGN) Company Profile
OGN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
OGN
Organon Co
|
8.76 | 2.26B | 6.28B | 700.00M | 537.00M | 2.6922 |
|
LLY
Lilly Eli Co
|
1,038.40 | 924.53B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
218.66 | 529.01B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
214.35 | 383.08B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVO
Novo Nordisk Adr
|
62.33 | 253.81B | 46.69B | 15.29B | 9.25B | 3.4329 |
|
NVS
Novartis Ag Adr
|
144.34 | 274.68B | 54.45B | 14.42B | 17.15B | 7.333 |
Organon Co Stock (OGN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-09 | 開始されました | Barclays | Underweight |
| 2025-10-27 | ダウングレード | Piper Sandler | Overweight → Underweight |
| 2025-05-02 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2024-09-06 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2023-11-03 | ダウングレード | Goldman | Buy → Neutral |
| 2023-09-21 | 開始されました | Barclays | Overweight |
| 2023-03-16 | 開始されました | Raymond James | Outperform |
| 2022-10-14 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2022-09-06 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2022-08-05 | ダウングレード | BofA Securities | Buy → Neutral |
| 2022-04-27 | 開始されました | Goldman | Buy |
| 2022-04-06 | 再開されました | Morgan Stanley | Equal-Weight |
| 2021-10-07 | 開始されました | Piper Sandler | Neutral |
| 2021-09-01 | 開始されました | BofA Securities | Buy |
| 2021-07-22 | 開始されました | Citigroup | Buy |
| 2021-06-15 | 開始されました | JP Morgan | Neutral |
| 2021-06-11 | 開始されました | Morgan Stanley | Equal-Weight |
| 2021-06-10 | 開始されました | Evercore ISI | Outperform |
すべてを表示
Organon Co (OGN) 最新ニュース
Sun Pharma looks to rise in US with $10 billion Organon buy - The Economic Times
Organon (OGN) Receives FDA Approval for Nexplanon Label Expansion to 5 Years - Intellectia AI
Organon wins FDA nod to expand use of Nexplanon birth control implant - Seeking Alpha
Organon Announces US Food and Drug Administration Approval of Supplemental New Drug Application Exte - PharmiWeb.com
Organon Announces US Food and Drug Administration Approval of Supplemental New Drug Application Extending Duration of Use of NEXPLANON® (etonogestrel implant) 68 mg Radiopaque - The AI Journal
Birth control implant Nexplanon now approved to last 5 years in US - Stock Titan
About Us - FinancialContent
Organon (OGN) Receives FDA Approval to Extend NEXPLANON Use to 5 Years - Intellectia AI
Organon (OGN) Receives FDA Approval for NEXPLANON Extended Use Up to 5 Years - Intellectia AI
Performance Recap: Whats the beta of Organon Co stockJuly 2025 Earnings & Detailed Earnings Play Alerts - baoquankhu1.vn
Global Organon employees on leading Pride Network and building inclusive workplaces - attitude.co.uk
Earnings Recap: Whats the beta of Organon Co stockLong Setup & Daily Chart Pattern Signals - baoquankhu1.vn
Organon (OGN) Increases Despite Market Slip: Here's What You Need to Know - sharewise.com
Organon (OGN) Exceeds Market Returns: Some Facts to Consider - Yahoo Finance
Organon and Co put volume heavy and directionally bearish - TipRanks
Nordea Investment Management AB Has $31.71 Million Position in Organon & Co. $OGN - MarketBeat
Validea Kenneth Fisher Strategy Daily Upgrade Report2/14/2025 - Intellectia AI
Organon & Co. (OGN) Stock Analysis: Exploring a 15% Potential Upside Amidst Diverse Product Portfolio - DirectorsTalk Interviews
Aug Levels: Will Organon Co stock see PE expansionEarnings Recap Report & High Yield Equity Trading Tips - Bộ Nội Vụ
Organon Shares Show Signs of a Turnaround - AD HOC NEWS
Responsive Playbooks and the OGN Inflection - Stock Traders Daily
Short Squeeze: How Organon Co stock reacts to inflationary pressuresCPI Data & Precise Buy Zone Tips - moha.gov.vn
Organon & Co. (NYSE:OGN) Receives Average Recommendation of "Reduce" from Analysts - MarketBeat
Organon & Co. $OGN Shares Sold by Philip James Wealth Mangement LLC - MarketBeat
Why Organon (OGN) Is Up 13.4% After Expanding Nilemdo Rights In Six European Markets - Yahoo Finance
Assessing Organon (OGN) Valuation After Short Term Share Price Momentum And Long Term Weak Returns - Yahoo Finance
Organon poised to extend rally to seventh consecutive session - MSN
Assessing Organon (OGN) Valuation After New Nilemdo Cholesterol Therapy Agreement - simplywall.st
Organon, Daiichi Sankyo Europe enter commercialization pact for Nilemdo - TipRanks
Organon Enters into a Commercialization Agreement for Daiichi Sankyo's Nilemdo®? in France, Denmark, Iceland, Sweden, Finland and Norway - marketscreener.com
Organon Enters into a Commercialization Agreement for Daiichi Sankyo’s Nilemdo - Business Wire
Organon Named Top Dividend Stock With Insider Buying and 0.99% Yield (OGN) - Nasdaq
Organon & Co. (OGN) Stock Analysis: Exploring The 25.77% Potential Upside For Investors - DirectorsTalk Interviews
Is Organon (NYSE:OGN) A Risky Investment? - 富途牛牛
Organon & Co. Sees Unusually Large Options Volume (NYSE:OGN) - MarketBeat
Great week for Organon & Co. (NYSE:OGN) institutional investors after losing 51% over the previous year - simplywall.st
Organon (OGN) Surpasses Market Returns: Some Facts Worth Knowing - Yahoo Finance
Samsung Bioepis Denies Organon Deal Rumors - Citeline News & Insights
Samsung Bioepis pursues direct sales by weighing Organon acquisition to boost profitsCHOSUNBIZ - Chosunbiz
Samsung Bioepis reviews Organon acquisition to boost direct biosimilar salesCHOSUNBIZ - Chosunbiz
Mixed Martial Arts Group Limited Stock Analysis and ForecastTechnical Resistance Breaks & Stay One Step Ahead of Risk Events - earlytimes.in
Organon & Co. (NYSE:OGN) Upgraded at Wall Street Zen - MarketBeat
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know - sharewise.com
Understanding the Setup: (OGN) and Scalable Risk - Stock Traders Daily
Will Organon Co 7XP stock outperform value peersMarket Growth Report & Fast Exit and Entry Trade Guides - moha.gov.vn
Volume Summary: How Organon Co stock reacts to inflationary pressuresBreakout Watch & Expert-Curated Trade Recommendations - moha.gov.vn
Organon & Co. (OGN) Stock Analysis: A Closer Look at Its 31.61% Potential Upside and What It Means for Investors - DirectorsTalk Interviews
Does Organon’s 50% Share Price Slide Signal Opportunity in 2025? - Yahoo Finance
Gilman Hill Asset Management LLC Reduces Position in Organon & Co. $OGN - MarketBeat
Here is What to Know Beyond Why Organon & Co. (OGN) is a Trending Stock - sharewise.com
Organon (OGN) Beats Stock Market Upswing: What Investors Need to Know - sharewise.com
Organon Co (OGN) 財務データ
収益
当期純利益
現金流量
EPS
Organon Co (OGN) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Drinane Juliana Papa | Interim Head of Mfg & Supply |
Nov 07 '25 |
Option Exercise |
0.00 |
3,626 |
0 |
18,417 |
| Arjona Ferreira Juan Camilo | Head of R&D & CMO |
Nov 07 '25 |
Option Exercise |
0.00 |
6,446 |
0 |
31,223 |
| Holzbaur Lynette | SVP and Corporate Controller |
Nov 07 '25 |
Option Exercise |
0.00 |
2,417 |
0 |
15,365 |
| Holzbaur Lynette | SVP and Corporate Controller |
Nov 05 '25 |
Option Exercise |
0.00 |
3,037 |
0 |
13,814 |
| Arjona Ferreira Juan Camilo | Head of R&D & CMO |
Aug 11 '25 |
Option Exercise |
0.00 |
11,519 |
0 |
28,899 |
| COX CARRIE SMITH | Director |
May 14 '25 |
Buy |
8.07 |
12,469 |
100,591 |
12,469 |
| Falcione Aaron | Chief Human Resources Officer |
May 07 '25 |
Buy |
8.77 |
5,500 |
48,235 |
62,974 |
| Weaver Kirke | Gen. Counsel & Corp. Secy. |
May 06 '25 |
Buy |
9.21 |
8,045 |
74,054 |
52,489 |
| Karp Daniel | Executive VP, Corp. Dev. |
May 06 '25 |
Buy |
8.24 |
3,500 |
28,828 |
46,669 |
| WALSH MATTHEW M | Chief Financial Officer |
May 05 '25 |
Buy |
8.82 |
11,400 |
100,548 |
144,484 |
1.85%
3.01%
大文字化:
|
ボリューム (24 時間):